Selective scavenging of the genotoxic impurity methyl p-toluenesulfonate from pharmaceutical formulations

Separation and Purification Technology

Volumn 103, Issue , 2013, Pages 173-179

  Kecili, Rüstem ^a,b   Billing, Johan ^a   Leeman, Mats ^a   Nivhede, David ^a   Sellergren, Börje ^b   Rees, Anthony ^c   Yilmaz, Ecevit ^a  

^a MIP Technologies AB   (Sweden)

^b TU DORTMUND UNIVERSITY   (Germany)

^c BIOTAGE AB   (Sweden)

Author keywords

Genotoxic impurities; Methyl p toluenesulfonate; Pharmaceutical formulations

Indexed keywords

2-PROPANOL; ACTIVE PHARMACEUTICAL INGREDIENTS; GENOTOXIC IMPURITIES; MACROPOROUS; P-TOLUENESULFONATES; PHARMACEUTICAL FORMULATION; POLYSTYRENE DIVINYLBENZENES; REMOVAL EFFICIENCIES; TIME COURSE;

DRUG PRODUCTS; IMPURITIES; POLYSTYRENES; POROUS SILICON; SILICA;

REMOVAL;

EID: 84869868250     PISSN: 13835866     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seppur.2012.09.028     Document Type: Article

References (19)

1. A. Cheminat, C. Benezra, M.J. Farral, and J.M.J. Frechet Use of polymeric nucleophiles for the selective binding and removal of α-methylene- γ-butyrolactone allergens from complex mixtures Tetrahedron Lett. 21 1980 617 619
2. D.L. Flynn, J.Z. Crich, R.V. Devraj, S.L. Hockerman, J.J. Parlow, M.S. South, and S. Woodard Chemical library purification strategies based on principles of complementary molecular reactivity and molecular recognition J. Am. Chem. Soc. 119 1997 4874 4881
3. G.M. Coppola A new scavenger resin for amines Tetrahedron Lett. 39 1998 8233 8236
4. K. Sandhya, and B. Ravindranath Comparative efficacy of polyamine-based scavenger resins Int. J. Org. Chem. 2 2012 71 74
5. M.D. LeVan Fundamental of Adsorption 1996 Kluwer Academic Publishers Norwell, MA
6. F. Rouqueol, J. Rouquerol, and K. Sing Adsorption by Powders and Porous Solids: Principles, Methodology and Applications 1999 Academic Press New York
7. C. Lee, R. Helmy, C. Strulson, J. Plewa, E. Kolodziej, V. Antonucci, B. Mao, C.J. Welch, Z. Ge, and M.A. Al-Sayah Removal of electrophilic potential genotoxic impurities using nucleophilic reactive resins Org. Process Res. Dev. 14 4 2010 1021 1026
8. R. Kecili, D. Nivhede, J. Billing, M. Leeman, B. Sellergren, and E. Yilmaz Removal of acrolein from active pharmaceutical ingredients using aldehyde scavengers Org. Process Res. Dev. 16 6 2012 1225 1229
9. G. Székely, J. Bandarraa, W. Heggie, B. Sellergren, and F.C. Ferreira Organic solvent nanofiltration: a platform for removal of genotoxins from active pharmaceutical ingredients J. Membr. Sci. 381 2011 21 33
10. G. Székely, J. Bandarra, W. Heggie, F.C. Ferreira, and B. Sellergren Design, preparation and characterization of novel molecularly imprinted polymers for removal of potentially genotoxic 1,3-diisopropylurea from API solutions Sep. Purif. Technol. 86 2012 190 198
11. G. Székely, J. Bandarra, W. Heggie, B. Sellergren, and F.C. Ferreira A hybrid approach to reach stringent low genotoxic impurity contents in active pharmaceutical ingredients: combining molecularly imprinted polymers and organic solvent nanofiltration for removal of 1,3-diisopropylurea Sep. Purif. Technol. 86 2012 79 87
12. S.G. Del Blanco, L. Donato, and E. Drioli Development of molecularly imprinted membranes for selective recognition of primary amines in organic medium Sep. Purif. Technol. 87 2012 40 46
13. M. Rios The impact of impurity analysis on future regulations Pharm. Technol. 2 2007
14. C. Gerber, and H.G. Toelle What happened: the chemistry side of the incident with EMS contamination in Viracept tablets Toxicol. Lett. 190 2009 248 253
15. L. Müller, and T. Singer EMS in Viracept - the course of events in 2007 and 2008 from the non-clinical safety point of view Toxicol. Lett. 190 2009 243 247
16. W. Armarego Purification of Laboratory Chemicals 2003 Elsevier Science ISBN 0-7506-7571-3
17. L. Müller, R.J. Mauthe, C.M. Riley, M.M. Andino, D.D. Antonis, C. Beels, J. DeGeorge, A.G. De Knaep, D. Ellison, J.A. Fagerland, R. Frank, B. Fritschel, S. Galloway, E. Harpur, C.D. Humfrey, A.S. Jacks, N. Jagota, J. Mackinnon, G. Mohan, D.K. Ness, M.R. O'Donovan, M.D. Smith, G. Vudathala, and L. Yotti A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity Regul. Toxicol. Pharm. 44 2006 198 211
18. K.L. Dobo, N. Greene, M.O. Cyr, S. Caron, and W.W. Ku The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development Regul. Toxicol. Pharm. 44 2006 282 293
19. European Medicines Agency (EMEA), Committee for Medicianal Products for Human Use (CHMP). Guidelines on the Limits of Genotoxic Impurities, London, February 2008.